aTyr Pharma (ATYR) Fundamental Analysis: Revenue, Earnings & Valuation

3.28 / 10

Netural

Fundamentals rate Neutral with a 3.3/10 quality. Profit‑MV and Cash‑MV are positive, but Asset‑MV, Revenue‑MV and tax ratios lag, yielding overall challenging financial health.

Analysis Checks(6/10)

Revenue-MV

Value-0.08

Score1/3

Weight16.33%

1M Return5.44%

Inventory turnover ratio

Value106.57

Score3/3

Weight19.82%

1M Return6.65%

Gross profit margin (%)

Value100.00

Score1/3

Weight0.77%

1M Return0.36%

Profit-MV

Value0.68

Score2/3

Weight18.64%

1M Return6.36%

Income tax / Total profit (%)

Value22.35

Score1/3

Weight0.46%

1M Return0.21%

Current assets turnover ratio

Value0.00

Score2/3

Weight4.28%

1M Return1.91%

Fixed assets turnover ratio

Value0.02

Score3/3

Weight3.95%

1M Return1.76%

Cost of sales ratio (%)

Value57.03

Score3/3

Weight9.85%

1M Return4.08%

Asset-MV

Value-0.55

Score0/3

Weight7.65%

1M Return2.73%

Cash-MV

Value0.03

Score2/3

Weight18.26%

1M Return6.19%

Is ATYR fundamentally strong?

ATYR scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -108.11% ROE, -39012.11% net margin, -0.99 P/E ratio, 1.10 P/B ratio, and 6.98% earnings growth, these metrics solidify its Netural investment rating.